Recombinant Sialyltransferase Infusion Mitigates Infection-Driven Acute Lung Inflammation

Mehrab Nasirikenari1†, Amit A. Lugade2, Sriram Neelamegham3, Zhongwei Gao4, Kelley W. Moremen4, Paul N. Bogner5, Yasmin Thanavala2 and Joseph T. Y. Lau1*

1 Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States, 2 Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States, 3 Department of Chemical and Biomedical Engineering, University at Buffalo, Buffalo, NY, United States, 4 The Complex Carbohydrate Research Center, University of Georgia, Athens, GA, United States, 5 Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States

Inappropriate inflammation exacerabtes a vast array of chronic and acute conditions with severe health risks. In certain situations, such as acute sepsis, traditional therapies may be inadequate in preventing severe organ damage or death. We have previously shown cell surface glycan modification by the circulating sialyltransferase ST6Gal-1 regulates de novo inflammatory cell production via a novel extrinsic glycosylation pathway. Here, we show that therapeutic administration of recombinant, bioactive ST6Gal-1 (rST6G) mitigates acute inflammation in a murine model mimicking acute exacerbations experienced by patients with chronic obstructive pulmonary disease (COPD). In addition to suppressing proximal neutrophil recruitment at onset of infection-mediated inflammation, rST6G also muted local cytokine production. Histologically, exposure with NTHI, a bacterium associated with COPD exacerbations, in rST6G-treated animals revealed consistent and pronounced reduction of pulmonary inflammation, characterized by smaller inflammatory cuffs around bronchovascular bundles, and fewer inflammatory cells within alveolar walls, alveolar spaces, and on pleural surfaces. Taken together, the data advance the idea that manipulating circulatory ST6Gal-1 levels has potential in managing inflammatory conditions by leveraging the combined approaches of controlling new inflammatory cell production and dampening the inflammation mediator cascade.

Keywords: sialylation, ST6Gal-1, inflammation, infection, airway, extrinsic glycosylation

INTRODUCTION

Acute inflammation is protective and intrinsic to a healing process. However, dysregulated, excessive, or persistent inflammation is detrimental and is often implicated in chronic conditions including cardiovascular, respiratory, and rheumatic diseases, and in extreme cases, systemic inflammatory response syndromes with high risks for mortality. Previously we provided evidence that a glycan-modifying enzyme present in systemic circulation is a potent regulator of inflammatory cell production (1–3). This enzyme, the ST6Gal-1 sialyltransferase, is regarded as a resident of the Golgi-ER secretory network, mediating the attachment of α(2,4)-linked sialic acid residues to exposed lactosaminyl-bearing nascent glycoproteins during intracellular biosynthetic transit. However, there is a significant pool of extracellular ST6Gal-1, particularly in the blood (5).
It has been known for a number of decades that changes in the level of circulatory ST6Gal-1 and the circulatory sialyl-glycan structures constructed by ST6Gal-1 are associated with a diverse array of clinical conditions including stress (6), atherosclerosis (4, 7), alcoholism (8, 9), as well as certain cancers, particularly colon and breast cancers, and multiple myeloma (10–12). Studies in the 1980’s have established that elevated release of ST6Gal-1 into the blood was a component of the hepatic acute phase response (13, 14). Within the last decade, there has been a renewed interest implicating ST6Gal-1 expression in chemoresistance (15), TNF and EGF-mediated signal transduction (16, 17), maintenance of pluripotentency in stem cells (18, 19), and cancer (10, 20, 21). The renewed interest has been based on the assumption of cell-autonomously expressed enzyme, and insight into the functional relevance of ST6Gal-1 released into the blood has remained relatively overlooked.

In a departure from the canonical mode of Golgi-ER glycosylation, which is a cell-autonomous and intracellular process, the extracellular, blood ST6Gal-1 remodels glycans on target cell surfaces in a novel extrinsic mechanism, which is not cell-autonomous (22, 23). Two genetically modified mouse models were used in these studies. The first, St6gal1-KO, was globally ST6Gal-1 deficient (24). The other, St6gal1-dP1, was deficient only in the liver-derived extracellular pool of ST6Gal-1 in the blood (25). Comparative analysis of these models revealed an overly robust inflammation and exaggerated inflammatory cell production associated with ST6Gal-1 deficiency. Exaggerated inflammation was attributed to deficiency only in the circulating extracellular pool, and not in the intracellular secretory apparatus-bound enzyme (1–3, 5). Lack of circulating ST6Gal-1 resulted in an exaggerated neutrophilic peritonitis upon challenge with Salmonella typhimurium or with the sterile eliciting agent, thioglycollate (2, 25). Circulatory ST6Gal-1 deficiency also resulted in more acute Th2 pulmonary inflammation with excessive eosinophil infiltration and elevated inflammatory cytokine release in OVA-sensitized mice (3). Recently, we observed that systemic ST6Gal-1 modifies the Granulocyte-Monocyte Progenitor (GMP) subset of hematopoietic progenitors, attenuating the production of granulocytes by blunting the transition of GMPs into Granulocyte Progenitors (1), thus providing a mechanistic explanation of how insufficiency in the blood-borne pool of ST6Gal-1 promotes a generally pro-inflammatory condition with excessive granulocyte production. We recently showed that subcutaneous implantation of localized B16 melanoma engineered to overexpress ST6Gal-1 could partially alleviate neutrophilic airway inflammation when challenged intratracheally with LPS in mice (1). Extracellular, systemic ST6Gal-1 was identified recently to be a pro-survival factor in transitional B cell development in the marrow, supporting a concept that circulating ST6Gal-1 is a conveyer of systemic cues guiding the development of multiple branches of immune cells (26).

In the present report, we tested the hypothesis that elevating blood ST6Gal-1 activity, by directly infusing a recombinant form of ST6Gal-1 (rST6G), can have therapeutic value in dampening inflammation. Lung diseases such as Chronic Obstructive Pulmonary Disease (COPD), the 4th leading cause of death worldwide, are characterized by episodic bouts of acute inflammation. These acute exacerbations, triggered by bacterial and viral infections, allergens, or other noxious stimuli, lead to an influx of inflammatory immune cells, predominantly granulocytes and macrophages, which drive disease pathology (27, 28). In the most severe forms, these episodes of immune cell recruitment can be directly life threatening, and at best they promote long-term airway destruction leading to permanently diminished airway functions. We used a murine model of acute airway inflammation elicited by NTHI (Non-typable Haemophilus influenza), an opportunistic pathogen common in acute exacerbations of COPD (27, 28). Repeated exposure of mice to NTHI recapitulated many of the features of airway damage seen in human COPD including induction and persistence of perivascular lymphocytic infiltrates and tissue destruction where the initial influx of inflammatory cells is thought to contribute centrally to drive organ damage in later stages (29).

We observed that animals receiving rST6G 2 h after an NTHI instillation had strikingly less acute inflammation with reduced pathology and less neutrophil infiltration into the lung, when compared to animals receiving only saline. Furthermore, rST6G treated animals had notably blunted local release of inflammatory cytokines. Ex vivo treatment of airway macrophages with rST6G resulted in muted NTHI –dependent production of inflammatory mediators. The data point to the value of rST6G administration in alleviating inflammation by suppressing new inflammatory cell production and in mitigating excessive inflammation by blunting the release of inflammatory cytokines.

RESULTS
Reduced Circulatory ST6Gal-1 Is Associated With More Severe Acute Airway Inflammation
To validate that there is an inverse relationship between the naturally occurring ST6Gal-1 in circulation and the need to produce new inflammatory cells during demand granulopoiesis, we subjected naïve, native C57BL/6 mice to a challenge with NTHI directly into the airways. NTHI elicits a Type 1 immune response in the airways that is dominated by neutrophilic infiltration in the initial phase. Circulatory ST6Gal-1 was monitored in these animals by assessing the enzymatic ability to form α2,6-sialyl linkages onto Gal(β1,4)GlcNAc acceptor substrate. NTHI exposure generated a pronounced but transient depression of circulatory ST6Gal-1 activity to ~30% of baseline levels at 7 h (Figure 1, left). In contrast, other sialyltransferase activities in the blood, specifically those forming the α2,3-sialyl structures on Gal(β1,4)GlcNAc and mediated by the sialyltransferases ST3Gal-3,–4, or–6, were not altered upon NTHI exposure (Figure 1, right).

We reported previously that insufficient circulatory ST6Gal-1 levels result in accelerated de novo granulocyte accumulation (1–3). Here, we validated this observation in the NTHI model of acute airway inflammation. The globally ST6Gal-1 null mouse, St6gal1-KO, and the St6gal1-dP1 mouse with deficiency only in
Moreover, nearly identical neutrophils were generated independently by different strategies. Neutrophils dominated the inflammatory cell infiltrate into the airway in lavage fluid (BALF) at 18 h in native C57BL/6 (wild-type) animal, and neutrophils comprised 75% of the total recovered BALF cells (Figure 2B). This result, which is more fully presented in Supplemental Table 1A, strongly supports the conclusion that insufficiency in circulatory ST6Gal-1 activity can also be attenuated by raising circulatory ST6Gal-1. We further posit that infusion of pure, recombinant ST6Gal-1 (rST6G), resulting only in temporary elevation of blood ST6Gal-1 activity can be effective against infection-driven inflammation. To explore the potential therapeutic value of rST6G, this and all other following experiments were performed in the wild-type C57BL/6 mouse. A single bolus of rST6G in its present formulation, when infused into wild-type animals at baseline was rapidly cleared from the bloodstream in <1 h (see Supplemental Figure 1A). Despite the rapid clearance, a single ST6G infusion resulted in a striking decline in granulopoietic parameters within the bone marrow, with ~40% decrease in colony forming units in granulocyte (G), Monocyte (M) and GM-CFU s 7 h later (Figure 3A). Total marrow cellularity diminished overall by ~25%, resulting mostly from a 2-fold reduction in marrow neutrophils and a slight reduction in B220-positive cells, the two most-abundant marrow cell populations (Figure 3B). Blood differentials revealed an almost 50% reduction in total white cell counts, accountable by the diminution of circulatory lymphocyte numbers that are the major white cell constituents in the blood (Figure 3C). Curiously, circulatory neutrophils in the naïve wild-type animals were not altered, although at baseline only a minor (10–12%) percentage of the overall circulating white cells are granulocytes. The complete blood differential counts are presented in Supplementary Table 1B.

To assess the anti-inflammatory efficacy of systemically administered rST6G, NTHI-challenged C57BL/6 mice received 2 intravenous infusions of rST6G, the first at 2 h after receiving NTHI, and a booster at 10 h. Two intravenous rST6G infusions were used as a precaution, because we observed rapid clearance of the current formulation of rST6G from the blood (Supplemental Figure 1A). The two infusions 5, 8 h apart resulted in circulatory ST6Gal-1 activity that was 2-fold over baseline at 16h after the initial rST6G infusion (Supplemental Figure 1B). In cohorts receiving rST6G, BALF neutrophil counts were reduced by ~50% (Figure 4B). Only a slight (10%) reduction in overall BALF leukocyte counts was observed, due to a ~2.5-fold increase in recruited macrophage. Though the increase in recruited macrophage numbers was unexpected, it is noteworthy that animals with genetic ST6Gal-1 deficit had ~33% decrease in recruited macrophage numbers in the airway following NTHI exposure (see Supplementary Table 1A). Circulating blood counts, monitored at the time BALF was recovered, showed no differences between rST6G and sham animals. This is not unexpected, since circulating neutrophilia was noted to be extremely transient and...
limited to the first few hours after a peripheral acute challenge, including peritonitis by LPS or thioglycollate (2), airway eosinophilia by OVA to sensitized mice (3), and acute airway inflammation by LPS (30). Blinded histopathologic evaluation disclosed a consistent reduction in pulmonary inflammation among animals treated with rST6G. Compared to animals receiving saline, the rST6G treated group showed smaller inflammatory cuffs around bronchovascular bundles and fewer inflammatory cells within alveolar walls and alveolar spaces (Figures 4C,D). The histopathologic scoring is summarized in Supplemental Table 2. Most unexpectedly, the rST6G-treated group had strikingly lowered levels of inflammatory cytokines TNF-α, IL-1β, and IL-6 in the BALF. In fact, inflammatory cytokines were close to or below reliable assay detection limits in BALF from animals that received rST6G, when compared to easily quantifiable levels in sham treated animals (Figure 5).

To gain mechanistic insight into the blunted inflammatory cytokines released in the airways by rST6G treatment, despite the apparently paradoxical elevation of airway macrophage, one of the principal cell types along with epithelial cells responsible for the release of inflammatory cytokines (31, 32), we examined the response of primary airway macrophages. Airway macrophages isolated from the BALF of resting wild-type C57BL/6 mice were stimulated ex vivo with heat-killed NTHI in the presence or absence of rST6G. A reduction of NTHI-dependent release of TNF-α and IL-6 production was observed in the rST6G-treated macrophages (Figure 6A). This effect was not unique to airway macrophages, as bone marrow derived macrophages treated with rST6G also had a 3.5-fold reduction in TNF-α (Figure 6B). Interestingly, IL-10 production by NTHI stimulated BM macrophages was elevated in the rST6G treated cells, pointing tantalizingly to a possible additional pathway by which rST6G can mitigate acute inflammation. In these ex vivo experiments, 0.1 mM CMP-Sia was also included. We have observed that rST6G to have effect on suppressing macrophage activity ex vivo, even without added sialic acid donor substrate. Possibly, the leakage of sialic acid donor substrate from neighboring dying cells might be sufficient. However, we also observed that addition of CMP-Sia has the benefit of diminishing variability. In vivo, sialic acid donor substrate is believed to be supplied by activating platelets (23, 33).

In an earlier report, we showed that systemic ST6Gal-1 dampens granulopoiesis in the marrow by extrinsic modification of the hematopoietic progenitor cells through the attachment of α2,6-linked sialic acid residues, which can be monitored by the lectin, SNA (Sambucus nigra agglutinin) (22). Here, cell surface α2,6-sialylation status of airway macrophage recovered in the BALF of animals challenged in vivo with NTHI was assessed for changes in SNA reactivity. The data show a pronounced increase in cell surface SNA reactivity in cells from animals treated with rST6G, compared to saline treated animals (Figure 6C). This observation strongly suggests that...
FIGURE 3 | Intravenous rST6G infusion depresses myelopoiesis and alters inflammatory cell availability. WT mice receiving either a single 300 µg bolus of recombinant ST6Gal-1 (rST6G) or saline (PBS) were sacrificed 7 h later. Bone marrow cells from hind limbs and peripheral blood were isolated and analyzed as follows. (A) presents marrow progenitor clonogenic activity for granulocyte/monocyte (GM), granulocyte (G), or monocyte (M) progenitor colonies. The combined total colony formed is also shown (Total). Saline- (open bars) and rST6G-treated mice (n = 9 each group) were used with 4 × 10⁴ marrow cells were plated in Methocult M3534 to promote growth of myeloid progenitors for 10 days. *p < 0.01 rST6G compared to PBS. (B) summarizes the overall bone marrow cellularity of PBS (round symbols) and rST6G-treated (square symbols) animals, where each symbol denotes one animal. Total bone marrow cellularity (Total), and neutrophil and B cell numbers are shown. *p < 0.01. (C) Summarizes white cell counts in the blood as total white blood cell (WBC) count and differential count for lymphocyte (Lymph), neutrophil (Neu), monocyte, eosinophil and basophil (MEB). PBS (n = 8) or rST6G-treated animals (n = 9) were used. *p < 0.01.

FIGURE 4 | Acute airway inflammation induced by NTHI exposure is mitigated by rST6G infusion. (A) shows the intervention protocol where each animal received two 300 µg rST6G or saline/sham injections spaced 8 h apart with the first injection being at 2 h after NTHI challenge. Animals were sacrificed 18 h later and assessed for pulmonary inflammation. (B) Inflammatory cell accumulation in the BALF of the rST6G- and sham- (PBS) treated animals showing total BALF cells (Total), neutrophil (Neut), and macrophage accumulation (Macs). *p < 0.01. (C,D) Show the lung pathology of saline and rST6G-treated animals, respectively at 18 h.
rST6G introduced into systemic circulation were able to affect the pulmonary macrophages and blunt the release of inflammatory cytokines during an NTHI-elicited acute airway response.

DISCUSSION

It has long been known that changes in the level of circulatory ST6Gal-1 and the circulatory sialyl-glycan structures constructed by ST6Gal-1 are associated with a diverse array of clinical conditions including stress (6), atherosclerosis (4, 34), alcoholism (35, 36), as well as in a certain cancers, particularly colon, breast cancers and multiple myeloma (10–12). Studies in the 1980’s have established that elevated release of ST6Gal-1 into the blood was a component of the hepatic acute phase response (37, 38), although insight into the physiologic contribution of blood ST6Gal-1 remained largely elusive. Much is known about the catalytic specificity of this glycan-modifying enzyme, ST6Gal-1, in attachment of α2,6-linked sialic acid residues to exposed lactosaminyl-termini of glycoproteins (39, 40). However, the traditional paradigm of glycosylation was that of an intracellular process, where glycosyltransferases such as ST6Gal-1 reside within the Golgi-ER secretory apparatus and modify the transiting nascent glyco-conjugates in an individual cell-autonomous manner. In contrast, circulatory ST6Gal-1, which is secreted principally by the liver, is extracellular and operates by the novel extrinsic glycosylation mechanism that is non-cell autonomous. Extracellular ST6Gal-1 remodels marrow hematopoietic precursor cells, and in so doing, mutes the ability of the precursors to differentiate and proliferate (22).

Original studies from this laboratory uncovered a link between low circulating ST6Gal-1 and excessive de novo inflammatory cell production (2, 3, 5, 22). Later, we also showed that chronically raising blood-borne ST6Gal-1 activity by subcutaneous implantation of a B16 melanoma engineered to overexpress the secretory form of the enzyme was effective in diminishing production of new granulocytes by blunting the transition of GMP to GP in granulopoiesis, and this approach was effective in controlling sterile agent-induced inflammation (1). In the current report, we show that an infection-driven inflammation can also be controlled effectively by direct intravenous infusion of pure recombinant ST6Gal-1 protein, despite using a primitive rST6G formulation that is very rapidly cleared from the blood. We used a murine model of NTHI-elicited acute airway. NTHI commonly colonizes the lower airways of patients with chronic obstructive pulmonary disease (COPD) and frequently contributes to the acute exacerbations driving disease progression (41, 42). In the mouse, airway instillation of NTHI elicits an immediate acute lung inflammatory response characterized by severe neutrophil infiltration into the airway, and repeated exposure to NTHI reproduces and perpetuates many of the pathophysologic symptoms of COPD (43). Previously we showed that a sterile LPS induced airway inflammation in mice resulted in extrinsic sialylation of pulmonary and circulating leukocytes, and the extrinsic sialylation used sialic acid precursors from activated platelets (33). We showed here that NTHI-elicited acute lung inflammation is more severe in mice with circulatory ST6Gal-1 insufficiency, as characterized by a 1.5-fold exaggeration in the already severe neutrophil infiltration into the airway. In wild-type animals, the onset of NTHI-elicited pulmonary inflammation was coincident with a specific and transient dip in ST6Gal-1 activity in circulation. This observation further supports the idea that depressed circulatory ST6Gal-1 predisposes the host for pro-inflammatory conditions and inflammatory cell production.

The detailed mechanistic links of how cell surface sialylation affects overall hematopoietic cell behavior remains to be elucidated. However, ST6Gal-1-mediated attachment of α2,6-sialic acids on β1 integrin alters cellular adhesiveness (44, 45) leading to altered cell motility (46), cancer cell differentiation and progression (46). In this study, we show that a recombinant protein corresponding to the soluble form of ST6Gal-1 (rST6G) was effective in mitigating infection-driven acute inflammation. Technical challenges associated with this approach remain. Most notably, suboptimal pharmacokinetic properties and/or enzymatic instability (Supplemental Figure 1A) of the present rST6G form resulted in undesirably rapid lost from circulation in the mouse, and rST6G remains difficult to produce in large quantities. Despite these limitations, the data show that systemic rST6G administration reduces overall marrow cellularity, dramatically decreases marrow granulocyte pool, and decreases marrow G-, GM-, and G-CFU clonogenic activities (see Figure 3). In response to NTHI challenge in the airway, rST6G intervention after the onset of localized acute inflammatory response resulted in pronounced mitigation of inflammation. While reduced granulocyte accumulation by rST6G administration was predicted by prior results, the muted release of inflammatory cytokines TNFa, IL-1β, and IL-6 in the airways was unexpected. The data showed not only a profound suppression of inflammatory cytokine release in vivo, but airway
Inflammatory cytokine release by macrophage was attenuated by ST6Gal-1. (A) Macrophages were recovered from the BALF of 3 wild-type C57BL/6 mice (at rest). The pooled cells were plated into 5 replicate but identical wells for each determination. Groups of 5 macrophage wells were exposed ex vivo to 10^5 CFU/ml heat-killed NTHI either in the absence or presence (20 µg/ml) of rST6G and CMP-Sia (100 µM) for 18 h. TNF-α and IL-6 released into the media was measured next day. *p < 0.001. (B) Bone marrow-derived macrophages were generated from marrow cells of C57BL/6 WT animals. The identically seeded cells, in groups of 5 wells per treatment, were exposed to heat-killed NTHI in the absence (control) or presence of rST6G (20 µg/ml) and CMP-Sia (100 µM) and incubated overnight (37°C and 5% CO2). TNF-α and IL-10 released into the media were assessed by ELISA. *p < 0.001 based on concentration values from five separate wells for each condition. All data are representative of six separate experiments. (C) BALF macrophage was recovered from C57BL/6 WT animals 18 h after oropharyngeal challenge with NTHI using the protocol in Figure 4A, either with rST6G (rST6G) or sham (PBS). Cell surface sialylation was measured using the α2,6-sialic acid-specific lectin, FITC conjugated Sambucus nigra agglutinin (SNA) by flow cytometry, as shown.

Macrophages in culture were less able to release TNF-α and IL-6 upon exposure to heat-killed NTHI. Bone marrow derived macrophages recapitulated not only the suppression of NTHI stimulated release of TNF-α but also the augmented release of the anti-inflammatory IL-10 by rST6G treatment ex vivo. The data advance the idea that the ability of circulatory ST6Gal-1 to mitigate inflammation is exerted through the concerted effects of at least two distinct target mechanisms, although additional targets may be likely. The known targets are the control of hematopoietic production of inflammatory cells and suppression of inflammatory cytokines.

Together, the data show that rST6G administration has novel therapeutic potential in the management of inflammatory conditions. This approach leverages the natural function of a natively circulatory glycan-modifying enzyme, the sialyltransferase ST6Gal-1. Intervention by systemic rST6G administration elevates circulating ST6Gal-1 activity, blunting the inflammatory cytokine cascade, and suppressing de novo production of inflammatory cells. While not specifically examined here, blunting these components of the initial inflammatory cascade should benefit in mitigating the lasting injury such as airway remodeling and organ injury at later stages of exposure to environmental insults.

MATERIALS AND METHODS

Animals

The St6gal1-dP1 and St6gal1-KO mouse strains were in the C57BL/6J background as described previously (2). Unless otherwise stated, C57BL6/J mice between 7 and 10 weeks of age were used, and both sexes were equally represented. Roswell Park Institute of Animal Care and Use Committee (IACUC) approved maintenance of animals and all procedures used under protocol 1071M. There is no involvement of human subjects or clinical specimens; ethics committee review is not required according to the local and national guidelines.

Recombinant ST6Gal-1 (rST6G) and Sialyltransferase Assays

rST6G is the recombinant secretory form of rat ST6Gal-1 where the catalytic domain was generated as a fusion protein encoding the following: NH2-signal sequence – 8x His tag – Avi tag – GFP – TEV protease cleavage site – ST6GAL1 catalytic domain – COOH (47). The construct was expressed in HEK293 cells; the recombinant protein was harvested and purified from the medium. The ST6Gal-1 catalytic domain was proteolytically released by TEV protease digestion and further purified (47, 48). Sialyltransferase assays were carried out as described previously (23).

Acute NTHI Exposure and Recombinant ST6Gal-1 (rST6G) Treatment

A frozen glycerol stock of NTHI strain 1479 (clinical isolate from a COPD exacerbation) was streaked on chocolate-agar plates, and single colonies were grown in a liquid culture of brain–heart infusion media supplemented with 10 µg/ml hemin and 10 µg/ml β-NAD (Sigma). After 3–4 h of culture in a 37°C shaking incubator, OD600 was determined to dilute the required
number of CFU to $2 \times 10^8$ CFU/ml in PBS. Bacteria were pelleted in microcentrifuge tubes at 13,000 $\times$ g for 10 min and washed twice in PBS. To initiate acute NTHI-mediated inflammation, mice were anesthetized by isoflurane inhalation, and 50 $\mu$l ($1 \times 10^6$ CFU) live NTHI diluted in PBS was used for oropharyngeal instillation using a 200-$\mu$l sterile pipette tip.

rST6G was injected i.v. (750 $\mu$g/CC in PBS) 2 and 14 h after NTHI exposure. Same volume of PBS was injected to control mice. After 18 h, mice were sacrificed by injection (i.p.) of two 0.5 ml Avertin (2.5 gr 2,2,2, Tribromethanol, 5 ml 2-methyl-2-butanol in 200 ml distilled water). Bronchoalveolar lavage (BAL) was performed post euthanization by opening the thoracic cavity to expose the trachea, which was cannulated with a 22-gauge i.v. catheter. PBS (750 $\mu$L) was injected and withdrawn from the lung two times using a tuberculin syringe. For cytokine assays, BAL fluid (200 $\mu$l) or serum (50 $\mu$l) was subjected to Luminex 100 multiplex assays using a capture bead system developed by Luminex Corporation (Austin, TX, USA). For pathohistologic evaluations, lungs were excised and fixed in 10% formaldehyde in PBS, paraffin embedded, sectioned, and stained with H&E. Lung pathology was evaluated by a board certified pulmonary pathologist blinded to the identity of the slides.

**Flow Cytometry, Cell Differentials, and Bone Marrow Analysis**

Flow cytometry was performed using anti-CD45 (hematopoietic cells), anti-Ly6G (neutrophils), anti-B220(B cells), anti-CD3 (T cells), anti-F4/80 (macrophage) anti-CD11c (dendritic cells) antibodies and SNA (Sambucus nigra lectin, Vector Laboratories, Peterborough, UK). All reagents were purchased from BioLegend (San Diego, CA). Cells were analyzed using BD LSR II flow cytometer (Becton Dickinson Immunocytometry Systems). For colony forming cell assays, marrow nucleated cells in a volume of 0.1 ml were plated in 0.9 ml of methylcellulose medium (MethoCult 3534, STEMCELL Technologies) in duplicate and placed in humidified incubator with 5% CO$_2$ at 37°C. Colonies containing at least 50 cells were counted 7 days after incubation.

**Ex vivo Labeling of Cells and Transfer Into Recipients**

Bone marrow cells were collected from hind-limbs of mice, either St6gal1-dp1 or C57BL/6 wild-type, re-suspended in RBC lysis buffer (0.8% NH$_4$Cl, 0.1 mM EDTA buffered with KHCO$_3$ to pH 7.4), washed and re-suspended in phosphate-buffered saline (PBS) with 0.5% BSA or fetal bovine serum and 2 mM EDTA, and then passed through a 100-$\mu$m cell strainer (BD Biosciences). Cells were centrifuged and re-suspended in the same buffer (up to $2 \times 10^8$ cells/ml), and 50 $\mu$l/ml of biotinylated antibodies (anti-cKit, anti-B220, anti-CD3, anti-TER119, anti-CD5) was added to the cell suspension. Partial neutrophil enrichment was accomplished by negative selection using magnetic microparticles according to the manufacturer’s protocol (STEMCELL Technologies, Vancouver, British Columbia, Canada). More than 60% of selected cells were neutrophils as verified by flow cytometry. To apply labeling with PKH26 and PKH67 (Sigma Chemical, St Louis, MO), cells were washed in RPMI medium (without serum), and 10$^7$ cells were re-suspended in 1 ml Diluent C (Sigma) and rapidly added to 1 mL of 4 $\mu$M PKH26 or PKH-67. The cells were incubated at 25°C for 5 min, terminated by the addition of 2.5% fetal calf serum. After labeling, the cells were washed twice with cold PBS and counted by hemocytometer. Differentially labeled donor cells were mixed 1:1 immediately before infusion into recipient animals. A small fraction of combined cells was labeled with neutrophil marker (anti-Ly6G antibody) and saved for measuring donor WT/dP1 neutrophil ratios. Each recipient received pooled cells consisting of 10$^7$ cells intravenously from each labeled group 2 h after NTHI BAL was performed 18 h after NTHI.

**Statistics**

Testing for differences between mean values was determined using either Students’ $T$-Test or two-way ANOVA with post-test comparisons in Graph Pad Prism 6 software (La Jolla, CA). $p < 0.05$ is considered significant.

**AUTHOR CONTRIBUTIONS**

MN designed the research, performed the experiments, and wrote the paper. AL designed the research and performed the experiments. ZG and KM generated the recombinant enzyme. SN wrote the paper. JL designed the research, coordinated project activities, and wrote the manuscript.

**ACKNOWLEDGMENTS**

This work was supported by a Program of Excellence in Glycosciences grant P01HL107146, R01AI056082, and R01AI140736. The core facilities of Roswell Park Cancer Institute used in this work were supported in part by NIH National Cancer Institute Cancer Center Support Grant CA076056. Additional supports were provided by P41GM103390 and P01GM107012-01 (to KM), and R01HL103411 (to SN).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2019.00048/full#supplementary-material

**REFERENCES**

1. Dougher CWL, Buffone A Jr, Nemeth MJ, Nasirikenari M, Irons EE, Bogner PN, Lau JTY. The blood-borne sialyltransferase ST6Gal-1 is a negative systemic regulator of granulopoiesis. J Leukoc Biol. (2017) 102:507–16. doi: 10.1189/jlb.3A1216-538RR
2. Nasirikenari M, Segal BH, Ostberg JR, Urbasic A, Lau JT. Altered granulopoietic profile and exaggerated acute neutrophilic inflammation in...
mice with targeted deficiency in the sialyltransferase ST6Gal Blood (2006) 108:3397–405. doi: 10.1182/blood-2006-04-141779.

3. Nasirikenari M, Chandrasekaran EV, Matta KL, Segal BH, Bogner PN, Lugade AA et al. Altered eosinophil profile in mice with ST6Gal-1 deficiency: an additional role for ST6Gal-1 generated by the P1 promoter in regulating allergic inflammation. J Leukoc Biol. (2010) 87:457–66. doi: 10.1189/jlb.1108704.

4. Sage AP, Mallatt Z. Sialyltransferase activity and atherosclerosis. Circ Res. (2011) 114:935–7. doi: 10.1161/CIRCRESAHA.114.303480.

5. Jones MB, Nasirikenari M, Feng L, Migliore MT, Choi KS, Kazim L, et al. Role for hepatic and circulatory ST6Gal-1 sialyltransferase in regulating myelopoiesis. J Biol Chem. (2010) 285:25009–17. doi: 10.1074/jbc.M110.104406.

6. Dable C, Flogel M, Maravic G, Lau C. Stress causes tissue-specific changes in the sialyltransferase activity. Z Naturforsch (2004) 59:276–80.

7. Gracheva EV, Golovanova NK, Ezhov MV, Malyshiev PP, Kuckharchuk VV. Plasma sialyltransferase activity in healthy subjects and atherosclerotic patients. Biochemistry (1999) 64:6313–14.

8. Stibler H, Borg S. Glycoprotein sialyl- and galactosyl transferase activities in erythrocyte membranes in alcoholic patients and healthy controls. Drug Alcohol Depend. (1986) 16:63–73.

9. Gong M, Garige M, Hirsch K, Rahman MN, Liver Galbeta1,4GlcNAc alpha2,6-sialyltransferase is down-regulated in human alcohols: possible cause for the appearance of asialoconjugates. Metabolism (2007) 56:1241–7. doi: 10.1016/j.metabol.2007.04.022.

10. Lu J, Gu J. Significance of beta-Galactoside alpha2,6-Sialyltransferase 1 in cancers. Molecules (2015) 20:7509–27. doi: 10.3390/molecules20057509.

11. Park JJ, Lee M. Increasing the alpha 2,6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer. Gut Liver (2013) 7:629–41. doi: 10.5009/gnl.2013.7.629.

12. Lu J, Isai T, Im S, Fukuda T, Hashii N, Takakura D, et al. beta-Galactoside alpha2,6-sialyltransferase 1 promotes transforming growth factor-beta-mediated epithelial-mesenchymal transition. J Biol Chem. (2014) 289:34627–41. doi: 10.1074/jbc.M114.593392.

13. Baumann H, Gauldie J. The acute phase response. Immunology Today (1994) 15:74.

14. Jamieson JC, McCaffrey G, Harder PG. Sialyltransferase: a novel acute-phase reactant. Comp Biochem Physiol B (1993) 105:29–34.

15. Chakraborty A, Dorsett KA, Trummell HQ, Yang ES, Oliver PG, Bonner JA, et al. ST6Gal1 sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage. J Biol Chem. (2018) 293:984–94. doi: 10.1074/jbc.M118.008354.

16. Holdbrooks AT, Britain CM, Bellis SL. ST6Gal-1 sialyltransferase promotes tumour necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor. J Biol Chem. (2018) 293:6160–12. doi: 10.1074/jbc.M117.801480.

17. Britain CM, Holdbrooks AT, Anderson JC, Willey CD, Bellis SL. Sialylation of EGF by the ST6Gal-1 sialyltransferase promotes EGF receptor activation and resistance to gefitinib-mediated cell death. J Ovarian Res. (2018) 11:12. doi: 10.1186/s13048-018-0385-0.

18. Wang YC, Stein JW, Lynch CL, Tran HT, Lee CY, Coleman R, et al. Glycosyltransferase ST6GALI contributes to the regulation of pluri potency in human pluripotent stem cells. Sci Rep. (2015) 5:13317. doi: 10.1038/ srep13317.

19. Schultz MJ, Holdbrooks AT, Chakraborty A, Grizzle WE, Landen CN, Buchbaum DJ, et al. Tumor-associated glycosyltransferase ST6Gal-1 regulates stem cell transcription factors and confers a cancer stem cell phenotype. Cancer Res. (2016) 76:3978–88. doi: 10.1158/0008-5472.CAN-15-2834.

20. Zhao Y, Li Y, Ma H, Dong W, Zhou H, Song X, et al. Modification of sialylation mediates the invasive properties and chemosensitivity of human hepatocellular carcinoma. Mol Cell Proteomics (2014) 13:520–36. doi: 10.1074/mcp.M113.034025.

21. Jones RB, Dorset KA, Hjelmeland AB, Bellis SL. The ST6Gal-1 sialyltransferase protects tumor cells against hypoxia by enhancing HIF-1alpha signaling. J Biol Chem. (2018) 293:5659–67. doi: 10.1074/jbc.RA117.011194.
43. Lugade AA, Vethanayagam RR, Nasirikenari M, Bogner PN, Segal BH, Thanavala Y. Nrf2 regulates chronic lung inflammation and B-cell responses to nontypeable Haemophilus influenzae. Am J Respir Cell Mol Biol. (2011) 45:557–65. doi: 10.1165/rcmb.2010-0321OC
44. Gu J, Itoh T, Sato Y, Kariya Y, Fukuda T. Importance of N-glycosylation on alpha5beta1 integrin for its biological functions. Biol Pharm Bull. (2009) 32:780–5. doi: 10.1248/bpb.32.780
45. Woodard-Grice AV, McBrayer AC, Wakefield JK, Zhuo Y, Bellis SL. Proteolytic shedding of ST6Gal-I by BACE1 regulates the glycosylation and function of alpha4beta1 integrins. J Biol Chem. (2008) 283:26364–73. doi: 10.1074/jbc.M800836200
46. Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR, Bellis SL. Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res. (2005) 65:4645–52. doi: 10.1158/0008-5472.can-04-3117
47. Meng L, Forouhar F, Thieker D, Gao Z, Ramiah A, Moniz H, et al. Enzymatic basis for N-glycan sialylation: structure of rat alpha2,6-sialyltransferase (ST6GAL1) reveals conserved and unique features for glycan sialylation. J Biol Chem. (2013) 288:34680–98. doi: 10.1074/jbc.M113.519041
48. Macnaughtan MA, Tian F, Liu S, Meng L, Park S, Azadi P, et al. 13C-sialic acid labeling of glycans on glycoproteins using ST6Gal-I. J Am Chem Soc. (2008) 130:11864–5. doi: 10.1021/ja804614w

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Nasirikenari, Lugade, Neelamegham, Gao, Moremen, Bogner, Thanavala and Lau. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.